Cargando…

Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

BACKGROUND: Patients with atrial fibrillation (AF) and hypertension are at high risk for stroke. Previous studies have shown elevated risk of stroke in patients with AF who have a history of hypertension (regardless of blood pressure [BP] control) and in patients with elevated BP. We assessed the as...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Meena P., Halvorsen, Sigrun, Wojdyla, Daniel, Thomas, Laine, Alexander, John H., Hylek, Elaine M., Hanna, Michael, Bahit, M. Cecilia, Lopes, Renato D., De Caterina, Raffaele, Erol, Cetin, Goto, Shinya, Lanas, Fernando, Lewis, Basil S., Husted, Steen, Gersh, Bernard J., Wallentin, Lars, Granger, Christopher B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845276/
https://www.ncbi.nlm.nih.gov/pubmed/26627878
http://dx.doi.org/10.1161/JAHA.115.002015
_version_ 1782428909988478976
author Rao, Meena P.
Halvorsen, Sigrun
Wojdyla, Daniel
Thomas, Laine
Alexander, John H.
Hylek, Elaine M.
Hanna, Michael
Bahit, M. Cecilia
Lopes, Renato D.
De Caterina, Raffaele
Erol, Cetin
Goto, Shinya
Lanas, Fernando
Lewis, Basil S.
Husted, Steen
Gersh, Bernard J.
Wallentin, Lars
Granger, Christopher B.
author_facet Rao, Meena P.
Halvorsen, Sigrun
Wojdyla, Daniel
Thomas, Laine
Alexander, John H.
Hylek, Elaine M.
Hanna, Michael
Bahit, M. Cecilia
Lopes, Renato D.
De Caterina, Raffaele
Erol, Cetin
Goto, Shinya
Lanas, Fernando
Lewis, Basil S.
Husted, Steen
Gersh, Bernard J.
Wallentin, Lars
Granger, Christopher B.
author_sort Rao, Meena P.
collection PubMed
description BACKGROUND: Patients with atrial fibrillation (AF) and hypertension are at high risk for stroke. Previous studies have shown elevated risk of stroke in patients with AF who have a history of hypertension (regardless of blood pressure [BP] control) and in patients with elevated BP. We assessed the association of hypertension and BP control on clinical outcomes. METHODS AND RESULTS: In ARISTOTLE (n=18 201), BP was evaluated as history of hypertension requiring treatment and elevated BP (systolic ≥140 and/or diastolic ≥90 mm Hg) at study entry and any point during the trial. Hazard ratios (HRs) were derived from Cox proportional hazards models including BP as a time‐dependent covariate. A total of 15 916 (87.5%) patients had a history of hypertension requiring treatment. In patients with elevated BP measurement at any point during the trial, the rate of stroke or systemic embolism was significantly higher (HR, 1.53; 95% confidence interval [CI], 1.25–1.86), as was hemorrhagic stroke (HR 1.85; 95% CI, 1.26–2.72) and ischemic stroke (HR, 1.50; 95% CI, 1.18–1.90). Rates of major bleeding were lower in patients with a history of hypertension (HR, 0.80; 95% CI, 0.66–0.98) and nonsignificantly lower in patients with elevated BP at study entry (HR, 0.89; 95% CI, 0.77–1.03). The benefit of apixaban versus warfarin on preventing stroke or systemic embolism was consistent among patients with and without a history of hypertension (P interaction=0.27), BP control at baseline (P interaction=0.43), and BP control during the trial (P interaction=0.97). CONCLUSIONS: High BP measurement at any point during the trial was independently associated with a substantially higher risk of stroke or systemic embolism. These results strongly support efforts to treat elevated BP as an important strategy to optimally lower risk of stroke in patients with AF. CLINICAL TRIAL REGISTRATION: URL: https://ClinicalTrials.gov/. Unique identifier: NCT00412984.
format Online
Article
Text
id pubmed-4845276
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48452762016-04-27 Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Rao, Meena P. Halvorsen, Sigrun Wojdyla, Daniel Thomas, Laine Alexander, John H. Hylek, Elaine M. Hanna, Michael Bahit, M. Cecilia Lopes, Renato D. De Caterina, Raffaele Erol, Cetin Goto, Shinya Lanas, Fernando Lewis, Basil S. Husted, Steen Gersh, Bernard J. Wallentin, Lars Granger, Christopher B. J Am Heart Assoc Original Research BACKGROUND: Patients with atrial fibrillation (AF) and hypertension are at high risk for stroke. Previous studies have shown elevated risk of stroke in patients with AF who have a history of hypertension (regardless of blood pressure [BP] control) and in patients with elevated BP. We assessed the association of hypertension and BP control on clinical outcomes. METHODS AND RESULTS: In ARISTOTLE (n=18 201), BP was evaluated as history of hypertension requiring treatment and elevated BP (systolic ≥140 and/or diastolic ≥90 mm Hg) at study entry and any point during the trial. Hazard ratios (HRs) were derived from Cox proportional hazards models including BP as a time‐dependent covariate. A total of 15 916 (87.5%) patients had a history of hypertension requiring treatment. In patients with elevated BP measurement at any point during the trial, the rate of stroke or systemic embolism was significantly higher (HR, 1.53; 95% confidence interval [CI], 1.25–1.86), as was hemorrhagic stroke (HR 1.85; 95% CI, 1.26–2.72) and ischemic stroke (HR, 1.50; 95% CI, 1.18–1.90). Rates of major bleeding were lower in patients with a history of hypertension (HR, 0.80; 95% CI, 0.66–0.98) and nonsignificantly lower in patients with elevated BP at study entry (HR, 0.89; 95% CI, 0.77–1.03). The benefit of apixaban versus warfarin on preventing stroke or systemic embolism was consistent among patients with and without a history of hypertension (P interaction=0.27), BP control at baseline (P interaction=0.43), and BP control during the trial (P interaction=0.97). CONCLUSIONS: High BP measurement at any point during the trial was independently associated with a substantially higher risk of stroke or systemic embolism. These results strongly support efforts to treat elevated BP as an important strategy to optimally lower risk of stroke in patients with AF. CLINICAL TRIAL REGISTRATION: URL: https://ClinicalTrials.gov/. Unique identifier: NCT00412984. John Wiley and Sons Inc. 2015-12-01 /pmc/articles/PMC4845276/ /pubmed/26627878 http://dx.doi.org/10.1161/JAHA.115.002015 Text en © 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Rao, Meena P.
Halvorsen, Sigrun
Wojdyla, Daniel
Thomas, Laine
Alexander, John H.
Hylek, Elaine M.
Hanna, Michael
Bahit, M. Cecilia
Lopes, Renato D.
De Caterina, Raffaele
Erol, Cetin
Goto, Shinya
Lanas, Fernando
Lewis, Basil S.
Husted, Steen
Gersh, Bernard J.
Wallentin, Lars
Granger, Christopher B.
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
title Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
title_full Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
title_fullStr Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
title_full_unstemmed Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
title_short Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
title_sort blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (aristotle) trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845276/
https://www.ncbi.nlm.nih.gov/pubmed/26627878
http://dx.doi.org/10.1161/JAHA.115.002015
work_keys_str_mv AT raomeenap bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT halvorsensigrun bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT wojdyladaniel bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT thomaslaine bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT alexanderjohnh bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT hylekelainem bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT hannamichael bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT bahitmcecilia bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT lopesrenatod bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT decaterinaraffaele bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT erolcetin bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT gotoshinya bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT lanasfernando bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT lewisbasils bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT hustedsteen bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT gershbernardj bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT wallentinlars bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT grangerchristopherb bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial
AT bloodpressurecontrolandriskofstrokeorsystemicembolisminpatientswithatrialfibrillationresultsfromtheapixabanforreductioninstrokeandotherthromboemboliceventsinatrialfibrillationaristotletrial